Inhibition of pro-inflammatory cytokine secretion- A new route to therapeutics of chronic inflammatory disease. Chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease, affect millions of people leading to considerable suffering, economic loss and premature death. Anti-TNF treatments have recently shown success in the treatment of rheumatoid arthritis, inflammatory bowel disease and other conditions, however, a substantial number of patients (~50%) do not re ....Inhibition of pro-inflammatory cytokine secretion- A new route to therapeutics of chronic inflammatory disease. Chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease, affect millions of people leading to considerable suffering, economic loss and premature death. Anti-TNF treatments have recently shown success in the treatment of rheumatoid arthritis, inflammatory bowel disease and other conditions, however, a substantial number of patients (~50%) do not respond to the current TNF treatments. Improved anti-TNF strategies would provide enhanced health outcomes and welcome relief to many Australians. In addition, the economic benefit of the TNF market is very substantial. Therefore the potential impact of this research is very high both for health care and economical potential.Read moreRead less
Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases. Diseases caused by malfunctioning of the body's immune system (inflammatory diseases) such as rheumatoid arthritis, psoriasis and Crohn's disease cause illness in all cultures and societies, and impose financial strain on health care providers. Current treatment relies on biopharmaceuticals that block inflammatory mediators in the body or with pharmaceuticals such as anti-inflammatory ....Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases. Diseases caused by malfunctioning of the body's immune system (inflammatory diseases) such as rheumatoid arthritis, psoriasis and Crohn's disease cause illness in all cultures and societies, and impose financial strain on health care providers. Current treatment relies on biopharmaceuticals that block inflammatory mediators in the body or with pharmaceuticals such as anti-inflammatory drugs; both these treatments may have serious side effects. Cpn10 suppresses the body's inflammatory response while maintaining immune function to combat infections. The project seeks to develop new, safe and effective biopharmaceuticals based on Cpn10 for the treatment of a variety of chronic inflammatory diseases and autoimmune disorders.Read moreRead less
NOVEL THERAPEUTICS FOR AUTOIMMUNE DISEASE USING MOUSE SCREENING MODELS. The project aims to use experimental models of human autoimmune disease in the mouse for the testing of developmental isoflavonoid compounds produced by the Industry Partner, for protective effects against autoimmunity. The murine models proposed will duplicate human autoimmune cardiomyopathy, systemic lupus erythematosus and multiple sclerosis, encompassing both organ-specific and systemic autoimmune diseases. Isoflavonoi ....NOVEL THERAPEUTICS FOR AUTOIMMUNE DISEASE USING MOUSE SCREENING MODELS. The project aims to use experimental models of human autoimmune disease in the mouse for the testing of developmental isoflavonoid compounds produced by the Industry Partner, for protective effects against autoimmunity. The murine models proposed will duplicate human autoimmune cardiomyopathy, systemic lupus erythematosus and multiple sclerosis, encompassing both organ-specific and systemic autoimmune diseases. Isoflavonoid protection is anticipated from the antioxidant, anti-inflammatory and oestrogenic characteristics of these compounds/Read moreRead less
Characterisation of the anti-inflammatory pathway targeted by chaperonin 10 (Cpn10). Diseases associated with excessive or inappropriate inflammation represent an enormous socioeconomic burden, and there is currently an urgent need to identify new targets for the development of more efficacious and safe treatments. This research seeks to provide such targets. The research may also lead to improvements in chaperonin 10 (Cpn10) treatment, which has already showing marked success in chronic inflamm ....Characterisation of the anti-inflammatory pathway targeted by chaperonin 10 (Cpn10). Diseases associated with excessive or inappropriate inflammation represent an enormous socioeconomic burden, and there is currently an urgent need to identify new targets for the development of more efficacious and safe treatments. This research seeks to provide such targets. The research may also lead to improvements in chaperonin 10 (Cpn10) treatment, which has already showing marked success in chronic inflammatory disease trials. Importantly, Cpn10 appears to be anti-inflammatory rather than immunosuppressive; a critical advantage over many current anti-inflammatory interventions. Immunosuppression can lead to increased infections, which can have serious consequences, especially in elderly patients.Read moreRead less
Cellular genomic approach to the pathogenesis of multiple sclerosis. This project compares the levels of gene usage in two important immune cell types between patients with multiple sclerosis and people who do not have the disease. It aims to identify the molecular basis for the disease, in order to identify new diagnostic, preventative and treatment options.
Investigating the atomic structure of an immune cell inhibitory receptor. T cells play a key role in the adaptive immune system, whose reactivity must be controlled to prevent aberrant reactivity. Central to the function of T cells is the T cell antigen receptor, and a host of co-stimulatory molecules, co-receptors and inhibitory receptors. This proposal, in partnership with Immutep Ltd, aims to gain a basic understanding of the structure and function of a key inhibitory receptor found on T cel ....Investigating the atomic structure of an immune cell inhibitory receptor. T cells play a key role in the adaptive immune system, whose reactivity must be controlled to prevent aberrant reactivity. Central to the function of T cells is the T cell antigen receptor, and a host of co-stimulatory molecules, co-receptors and inhibitory receptors. This proposal, in partnership with Immutep Ltd, aims to gain a basic understanding of the structure and function of a key inhibitory receptor found on T cells, termed the Lymphocyte activation gene-3 (LAG-3). The proposal utilises a combination of cellular immunology and structural biology to gain insight into the form and function of the LAG-3 molecule. Ultimately this fundamental knowledge can be used by the biotechnology industry.Read moreRead less
Exploring therapeutic approaches to combat Coeliac Disease. In Coeliac disease the immune system reacts to ingested wheat protein and attacks the tissue of the small intestine. The wheat protein activates certain immune cells and this initiates a destructive inflammation. In collaboration with the Australian-based company Nexpep, this project aims to develop therapeutics against Coeliac disease.